97 results about "Fosfomycin" patented technology

A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having a mass median aerodynamic diameter predominantly between 1 to 5μ, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.

The invention provides a preparation method of fosfomycin monoamine butantriol. The method comprises the following steps of: adding fosfomycin diamine butantriol salt into methanol, adding acid to adjust the pH to be between 4 and 7 at the temperature of between 5 DEG C below zero and 30 DEG C, filtering, removing filter residue, adding an organic solvent into the filtrate to separate out crystal, filtering, drying, and thus obtaining a fosfomycin monoamine butantriol finished product. The method is simple in reaction, the yield can reach 85 to 90 percent, the product content (the detection content can reach over 99 percent) is high, and the method is suitable for industrialized production and has great application value.

The invention relates to a synthesis method of an immobilized tungstophosphoric heteropoly acid catalyst and a use of the immobilized tungstophosphoric heteropoly acid catalyst in cis-propenylphosphonic acid epoxidation. The synthesis method of the immobilized tungstophosphoric heteropoly acid catalyst comprises 1, synthesizing low-carbon chain phosphotungstic heteropoly acid quaternary ammonium salt and 2, loading the phosphotungstic heteropoly acid quaternary ammonium salt on resin to obtain the immobilized tungstophosphoric heteropoly acid catalyst. The catalyst is prepared from easily available raw materials, effectively catalyzes cis-propenylphosphonic acid epoxidation to synthesize fosfomycin phenylethylamine salt, is convenient for recovery, has a long service life and can be recycled 5 times. The catalyst can reduce a fosfomycin phenylethylamine salt production cost and satisfies the current green chemical and atom economic requirements.

The invention relates to the biological medicine and biological catalytic field, in particular to a biological catalytic method for transforming the D-fosfomycin into the L-fosfomycin through a biological catalytic process, aiming to solve the puzzle to transform the D-fosfomycin into the L-fosfomycin. The strain with catalytic ability is proliferated, centrifuged, harvested and inoculated into a cultivation substrate, which comprises the components by weight percentage of: 0.5-3 percent of D-fosfomycin, 0.5-1.0 percent of (NH4)2SO4, 0.2 percent of NaCl, 0.1 percent of KCl, 0.01-0.02 percet of MgSO4.7H2O, 0.01-0.03 percent of FeSO4.7H2O,0.05-0.15 percent of ,KH2PO4; the left volume is water, and the pH is 7.5. The sterilization is carried out at 121 DEG C for 20 minutes, and cultivation is made for 3-7 days under the temperature of 28-37 DEG C, and the rotation velocity of 150-250 rpm of the rocking bed. The qualitative and quantitative analysis on the L-fosfomycin in the fermentation liquid is carried out respectively through thin-layer chromatography and the method of bioassay disc. The invention provides a novel catalytic method for transforming the D-fosfomycin into the L-fosfomycin, and accomplishes the operable bio-catalysis of the D-fosfomycin.

There is proposed herein a process for production of composite antimicrobial preparations for parenteral administration, featuring a higher therapeutic efficiency in case of grave infection and inflammatory diseases. The proposed compositions include an active agent being fosfomycin and finely dispersed nanostructured silica dioxide, with a weight ratio from 10:1 to 75:1 respectively. The mentioned production process includes mixing fosfomycin with finely dispersed nanostructured silica dioxide. Its main difference is that the mixture of aforementioned substances with the mentioned weight ratio is exposed to mechanical processing by blow impact and abrasive actions until a portion of the fine powder fraction with particles smaller than 5 micrometers, contained in the mixture, increases to at least 25%. The so obtained mixture is used for injection preparations.

A drying method of fosfomycin calcium comprises the following steps: step 1, crushing a fosfomycin calcium monohydrate wet product; step 2, feeding the crushed fosfomycin calcium monohydrate wet product into a double-cone dryer, and then controlling a vacuum degree in the double-cone dryer to be 20-30Kpa; step 3, controlling the vacuum degree in the double-cone dryer to be 20-30Kpa and temperature to be 40-50DEG C, enabling the double-cone dryer to rotate at intervals, and carrying out drying for 16h; step 4, controlling the vacuum degree in the double-cone dryer to be smaller than or equal to 30Kpa, temperature to be 55-65DEG C and drying time to be 8-16h so as to enable fosfomycin calcium crystals to form lumps with 2-5cm diameters; and step 5, controlling the vacuum degree in the double-cone dryer to be smaller than or equal to 5Kpa, temperature to be 55-65DEG C and drying time to be longer than or equal to 8h so as to enable the water content of the dried fosfomycin calcium crystals to be 8.7-12.0%. In the invention, the double-cone dryer is used for drying, and spinning extrusion is carried out on the fosfomycin calcium crystals in the drying process so as to obtain fine lump solids.

The invention discloses a levo-fosfomycin dextro-phenethylamine salt and a detection method for an enantiomer thereof, and relates to the field of pharmaceutical analysis. The levo-fosfomycin dextro-phenethylamine salt and the enantiomer thereof are analyzed by using a high performance liquid chromatograph, and sample analysis is performed by adopting a negative ion exchange chiral column and a flowing phase of specific components and proportion. The method can be used for easily, rapidly and accurately analyzing and separating the levo-fosfomycin dextro-phenethylamine salt and the enantiomer thereof. The method has the advantages of high reproducibility, high separation degree, stability in detecting samples, and the like.

The invention relates to a grape seedless agent, in particular to a regulating agent which can lead the grape to be seedless, and aims at solving the problems that after the existing grape seedless agent is applied, the seedless rate of the grape and the percentage of fertile fruit of the flower are not ideal, the grape with different sizes occurred and the sweetness level is not increased obviously. The regulating agent is prepared by the following materials by weight ratio: 20 to 60g of phytokinin or cytokinin, 20 to 50g of gibberellin, 2 to 5g of fosfomycin sodium, 3 to 5g of florel, 1 to 2g of cycocel, 10 to 15g of organic nitrogen, 3 to 5g of paclobutrazol, 20 to 40g of vitamin E, vitamin B and vitamin C, 10 to 15g of kanamycin, 10 to 30g of 2-4-D and 3 to 5g of borax. The regulating agent has the advantages that the seedless rate of the grape can be up to 100 percent, the percentage of fertile fruit of the flower can be up to 90 percent, the fruits of medium and late maturing varieties are ripe in advance of 20 to 30 days, the sweetness level of the grape is increased by about 2 degrees, the content of dry matters are high and the storage is easy.

The invention provides a fosfomycin sodium composition lyophilized powder for injection, and relates to the technical field of medicines and medicine preparation. The fosfomycin sodium composition lyophilized powder for injection comprises the following raw materials in parts by weight: 7.26-9.17 parts of fosfomycin sodium, 7.02-8.97 parts of chitosan nanoparticle, and 81.38-87.10 parts of injection water. The fosfomycin sodium composition lyophilized powder for injection has the following advantages that (1) the antibacterial effect on klebsiella pneumoniae is good, the antibiotic sensitive rate is 89.9%, and the advantage in klebsiella pneumoniae producing ESBLs (Extended Spectyum beta Lactamase) is obvious; (2) the stability on beta-lactamase produced by gram-negative bacterium is increased, and the in-vivo distribution is good; (3) as the activity is improved, the medication period of a patient is shortened, and the possibility of untoward effect caused by the accumulation of fosfomycin sodium is reduced; and (4) the chitosan nanoparticle can replace mannitol to function as the lyophilization skeleton agent of the lyophilized powder, and the activation effect on a human body by the mannitol is eliminated.

The invention relates to a method for detecting fosfomycin sodium in pharmaceutical wastewater by adopting an ion chromatography. The method comprises the following steps that (1) chromatographic condition: chromatographic columns include a low-volume hydroxyl system cathodic protection column and a high-volume anion exchange separation column, a suppressor is an electrolytic film suppressor, an electrical conductivity detector is used, and leacheate is a sylvite solution; (2) the preparation of a standard solution: a standard product of the fosfomycin sodium is mixed with ultrapure water to obtain into the standard solution; (3) the pretreatment of a sample: a sample to be detected is filtered by using a 0.45mum filtering film and then processed by a C18 colonnette so that organic matters in the water sample are removed; (4) a detecting method: the standard solution is added in an ion chromatograph, then a spectrogram is recorded, the position of a standard peak is determined, the area of a fosfomycin sodium peak is calculated, and a standard curve is drawn according to the calculated area of the peak; a testing sample is added in the ion chromatograph, then a spectrogram is recorded, and the concentration of the sample is calculated according to the area of the fosfomycin sodium peak. The method provided by the invention has the advantages that the detection repeatability of the fosfomycin sodium in the pharmaceutical wastewater is good, the detection limit is low, the sensitivity is high, the operation is simple, the detecting condition is gentle, the detection equipment and instrument are widely applied, the source of a leacheate sylvite solution is wide, and the configuration is simple, and the method is widely used for detecting fosfomycin sodium in the industrial wastewater.

The invention provides a fosfomycin calcium composition freeze-dried tablet and a preparation method thereof, and relates to the technical field of medicines and medicine production. The fosfomycin calcium composition freeze-dried tablet comprises fosfomycin calcium, starch and cane sugar, wherein the starch and the cane sugar are used as auxiliary materials, and heating process processing is performed on common corn starch, so that the bonding and disintegrating functions of the starch in the tablet can be improved, and the formability of the tablet is improved; the fosfomycin calcium composition freeze-dried tablet only needs the starch and the cane sugar which are used as the auxiliary materials. The fosfomycin calcium composition freeze-dried tablet adopts a freeze-drying process that temperature is reduced and increased for two times, and the process that the temperature is reduced and increased for two times enables the formability of the tablet to be better, and increases the dissolution rate of the tablet, so that the bioavailability of the tablet is improved. The tablet disclosed by the invention overcomes the defects of a common fosfomycin calcium tablet, and has the characteristics that the types and the dosage of the auxiliary materials in the fosfomycin calcium tablet are reduced, the tablet has a high dissolution rate and high bioavailability, and the curative effect and the safety of clinical medication are guaranteed.

The invention provides a compound fosfomycin calcium drug. The active component of the compound fosfomycin calcium drug is composed of fosfomycin calcium, trimethoprim and glycyrrhizic acid in a weight ratio of (10-30): (5-10): (3-6). The invention provides a capsule of the compound fosfomycin calcium drug, and the capsules has good slow-release effect; and the compound fosfomycin calcium drug provided by the invention has better antibacterial effect compared with commercially-available related products.

The invention provides a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and an antimicrobial compound selected from nitrofurantoin, mecillinam, fosfomycin, cephalexin and faropenem, or a pharmaceutically acceptable derivative or prodrug thereof. These combinations are particularly useful for the treatment of microbial infections.